The disease control rate was 75.4%, with a median PFS of 5.8 months.43 In an ongoing phase III trial, first-line pemigatinib is compared with systemic gemcitabine/cisplatin in patients with advanced cholangiocarcinoma with FGFR2 rearrangements.44 The role of immunotherapy for iCCA has not yet been established, but is investigated in several clinical trials including the ongoing ABC-09 phase II trial and KEYNOTE-966 phase III trial (NCT03260712, NCT04003636). This evidence concerns the gene FGFR2 and cholangiocarcinoma.